Johnson & Johnson

Holdings as of Mar 31, 2026 · filed May 13, 2026

$652355946
Portfolio value
16
Positions
Source: SEC 13-F ↗
Original filing
# Holding Value % Port. Δ Shares Change (QoQ)
1 Protagonist Therapeutics Inc. $258143888 39.57% Held
2 Nanobiotix S.A. $173607200 26.61% Held
3 Meiragtx Holdings Plc $57511614 8.82% Held
4 Rapport Therapeutics, Inc. $55837537 8.56% Held
5 Cvrx, Inc. $38075185 5.84% Held
6 Contineum Therapeutics Inc. $25847999 3.96% Held
7 Legend Biotech Corporation $14735861 2.26% Held
8 Xencor, Inc. $9021628 1.38% Held
9 Procept Biorobotics Corporation $8952054 1.37% Held
10 Fate Therapeutics, Inc. $4054877 0.62% Held
11 Neumora Therapeutics, Inc. $3606418 0.55% Held
12 Rallybio Corporation $1371522 0.21% NEW BUY
13 Vor Biopharma, Inc. $958579 0.15% Held
14 Standard Biotools, Inc. $286791 0.04% Held
15 Nano-X Imaging Ltd. $189668 0.03% -75298 -47.40%
16 Adicet Bio, Inc. $155125 0.02% Held

Closed last quarter

Rallybio Corporation Lyell Immunopharma, Inc.

Holdings disclosed quarterly to the SEC on Form 13-F and may be up to 45 days old. Values as reported. For research only — not investment advice.